Jazz Pharmaceuticals PLC / Chimerix, Inc.

H3 K27M-mutant diffuse glioma

2K US cases/yr · $300M Analyst peak sales estimate for dordaviprone (consensus, 2025)

Disease Overview

H3 K27M-mutant diffuse glioma (formerly termed diffuse intrinsic pontine glioma or DIPG when arising in the brainstem) is a rare, aggressive midline CNS tumor defined by the WHO 2021 CNS5 classification as a distinct molecular entity driven by a lysine-to-methionine substitution at position 27 of histone H3. It occurs predominantly in pediatric and young adult patients, most commonly in the pons, thalamus, and spinal cord, and carries a median overall survival of approximately 9 to 11 months from diagnosis. There are no FDA-approved therapies specifically for H3 K27M-mutant glioma; standard of care has historically been focal radiation therapy, which provides transient symptom relief but no survival benefit beyond months. The tumor is functionally inoperable when located in the brainstem, and conventional chemotherapies and targeted agents have repeatedly failed in randomized trials. Pediatric brain tumors remain the leading cause of cancer death in children in the United States, with H3 K27M-mutant gliomas representing the single most lethal pediatric CNS diagnosis. The ACTION Phase 3 pivotal trial of dordaviprone, run under FDA Fast Track and Orphan Drug designations, enrolled newly diagnosed patients post-radiation. Dordaviprone received FDA accelerated approval (Modeyso) in August 2025 as the first therapy specifically indicated for recurrent H3 K27M-mutant diffuse glioma.

Competitive Landscape

The competitive landscape in H3 K27M-mutant diffuse glioma is thin by design: dordaviprone (Modeyso; Chimerix, now Jazz) is the first and only FDA-approved therapy specifically indicated for the disease following August 2025 accelerated approval, and it sits alone in the near-term commercial window. The closest pipeline competitors are ONC206 (Chimerix/Jazz internal follow-on imipridone), paxalisib (Kazia Therapeutics, PI3K/mTOR inhibitor in pediatric DIPG), ONC201 combination regimens being explored academically, and GD2-directed CAR-T programs from Stanford and others in early-phase pediatric trials. Broader diffuse midline glioma development also includes panobinostat (Secura Bio/Novartis) in academic trials, marizomib (Celgene/BMS, proteasome inhibitor, discontinued for DIPG after 2022 readout), and Day One Biopharmaceuticals' tovorafenib (Ojemda) which addresses BRAF-altered pediatric low-grade glioma — an adjacent but molecularly distinct pediatric CNS space. Standard of care remains focal radiation therapy alone for newly diagnosed patients; there is no approved systemic therapy other than dordaviprone. Jazz's strategic thesis centers on dordaviprone as a first-in-class CNS oncology asset with orphan pricing power, pediatric priority review voucher value, and a protected franchise in a white-space indication with no approved competitors.